27th April 2022 | Pharma Updates

GSK introduces COPD patients to once daily, single-inhaler-triple treatment

GlaxoSmithKline Pharmaceuticals has announced the availability of Trelegy Ellipta for patients suffering from Chronic Obstructive Pulmonary Disease (COPD).

Abu Dhabi Sovereign Fund investin Intas Pharma

Abu Dhabi Investment Authority (ADIA) is set to purchase around 3% of Intas Pharmaceuticals for $250-$270 million (2,000 crore) at a valuation of $8.5 billion (65, 000 crore).

Zydus received EUA for a two-dose vaccine against ZyCoV-D

Zydus Lifesciences Ltd. reported on Tuesday that its innovative Covid-19 vaccine, ZyCoV-D, has been granted Emergency Use Authorization (EUA) by the Drug Controller General of India (DCGI) as a two-dose vaccine.

DGCI approves vaccines under EUA for children aged 5 and up

Union Health Minister Dr. Mansukh Mandaviya claimed that India’s fight against COVID-19 is now stronger since additional vaccines have been licenced by CDSCO for the age group of 5-12 years in the fight against COVID-19.

Malaysia grants Biocon Biologics $90 million contract to produce human insulin

Malaysia’s largest biopharma has been awarded a three-year contract by the government to manufacture and distribute insulin to the country. Insugen will be manufactured and supplied to the Ministry of Health by Biocon Biologics.

Glenmark introduces Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes

Glenmark Pharmaceuticals announced on Monday the launch of a novel fixed-dose combination (FDC) of Teneligliptin and Pioglitazone for people with uncontrolled Type 2 diabetes in India.

Following the failure of a cancer medication, Nektar will lay off over 500 people

Nektar Therapeutics announced a restructure 11 days after the collapse of a four-year-old cooperation with Bristol Myers Squibb to develop Nektar’s bempegaldesleukin with BMS’ cancer blockbuster Opdivo.

Ferring Pharma develops an integrated R&D and manufacturing facility in Hyd

Ferring Pharmaceuticals unveiled its integrated R&D and production facilities in Hyderabad’s Genome Valley on Monday. The facility, which will research and commercialise novel pharmaceutical goods.